Hiromi Shibasaki

List of Publications by Year
in descending order

17	273	1040056 9	940533 16
papers	citations	h-index	g-index

17	17	17	230
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development and Validation of an LCâ€“MS/MS-Based Method for Quantifying Urinary Endogenous 6-Hydroxymelatonin. Chemical and Pharmaceutical Bulletin, 2022, 70, 375-382.	1.3	2
2	Influence of Anticoagulants and Storage Conditions During Blood Sample Collection on Determination of the 6Î²-hydroxycortisol/cortisol Ratio by LC-MS/MS. Bunseki Kagaku, 2022, 71, 357-363.	0.2	0
3	Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 317-324.	1.6	1
4	Dried blood spots analysis of 6Î²â€hydroxycortisol and cortisol using liquid chromatography/tandem mass spectrometry for calculating 6Î²â€hydroxycortisol to cortisol ratio. Journal of Mass Spectrometry, 2021, 56, e4790.	1.6	4
5	Midazolam Intoxication in a Premature Neonate. Clinical Therapeutics, 2020, 42, 946-951.	2.5	2
6	Sensitive and simultaneous quantitation of 6Î²â€hydroxycortisol and cortisol in human plasma by LCâ€MS/MS coupled with stable isotope dilution method. Journal of Mass Spectrometry, 2018, 53, 665-674.	1.6	9
7	Use of endogenous cortisol 6Î²-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors. Steroids, 2014, 87, 137-144.	1.8	8
8	Intraindividual and Interindividual Variabilities in Endogenous Cortisol 6Î²-Hydroxylation Clearance as an Index for In Vivo CYP3A Phenotyping in Humans. Drug Metabolism and Disposition, 2013, 41, 475-479.	3.3	18
9	Separation and quantitative determination of 6Î±-hydroxycortisol and 6Î²-hydroxycortisol in human urine by high-performance liquid chromatography with ultraviolet absorption detection. Analytical and Bioanalytical Chemistry, 2012, 402, 2945-2952.	3.7	7
10	Simultaneous determination of prednisolone, prednisone, cortisol, and cortisone in plasma by GCâ€“MS: Estimating unbound prednisolone concentration in patients with nephrotic syndrome during oral prednisolone therapy. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 870, 164-169.	2.3	35
11	Simultaneous determination of 6Î²-hydroxycortisol and cortisol in human urine by liquid chromatography with ultraviolet absorbance detection for phenotyping the CYP3A activity determined by the cortisol 6Î²-hydroxylation clearance. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 801, 165-171.	2.3	23
12	Simultaneous determination of endogenous and stable isotope-labelled 6Î²-hydroxycortisols in human urine by stable isotope dilution mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 794, 373-380.	2.3	12
13	EVIDENCE FOR THE VALIDITY OF CORTISOL 6Î²-HYDROXYLATION CLEARANCE AS A NEW INDEX FOR IN VIVO CYTOCHROME P450 3A PHENOTYPING IN HUMANS. Drug Metabolism and Disposition, 2003, 31, 1283-1287.	3.3	52
14	Simultaneous determination of endogenous and 13C-labelled cortisols and cortisones in human plasma by stable isotope dilution mass spectrometry. Biomedical Applications, 2000, 738, 119-127.	1.7	39
15	Simultaneous determination of 6Î²- and 6Î±-hydroxycortisols and 6Î²-hydroxycortisone in human urine by stable isotope dilution mass spectrometry. Biomedical Applications, 2000, 738, 367-376.	1.7	23
16	Synthesis of multi-labeled cortisols and cortisones with 2H and 13C for study of cortisol metabolism in humans. Steroids, 2000, 65, 180-189.	1.8	22
17	Diurnal rhythm in the plasma concentration of cortisol in paediatric patients with orthostatic dysregulation. Biological Mass Spectrometry, 1990, 19, 225-229.	0.5	16